We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Avanos Medical's (AVNS) App to Support Pain Management Process
Read MoreHide Full Article
Avanos Medical, Inc. (AVNS - Free Report) recently introduced its PainBlock Pro data collection and patient engagement app that enables healthcare providers to track patients’ recovery in real time for up to 10 days after surgery. The app/text message-based platform is easy to use and helps in tracking patient progress by collecting patient reported outcomes (PROs) through quick daily surveys, pre and post surgery, via the completion of the pain management therapy.
The launch of this app is another addition to Avanos Medical’s robust product portfolio, which is a significant contributor to the company’s top line.
Benefits of the New Technology
Per management, gathering real-time patient feedback forms a crucial step in getting patients back to the important things. The app helps healthcare providers to communicate with their patients with user-friendly technology, which gives key insight into the recovery process.
Image Source: Zacks Investment Research
Data collected from the aforementioned surveys can allow providers to develop customized pain management plans on the basis of critical factors that include patients’ level of pain, opioid consumption and overall satisfaction.
Market Prospects
Per a report by Grand View Research, the global patient engagement solutions market was worth $15.1 billion in 2020 and is projected to witness a CAGR of 21.4% from 2021 to 2028. Growing utilization of electronic health records for patient-centric care and the adoption of mobile health devices are the primary factors driving this market’s growth. Hence, this launch is well-timed for Avanos Medical.
Recent Development
Per the third-quarter 2021 earnings call, Avanos Medical continues to improve its product offerings entering the fourth quarter of the year to boost the efficacy and ease of use for its care partners.
Price Performance
Shares of this Zacks Rank #3 (Hold) company have lost 35.2% on a year-to-date basis against the industry’s growth of 3%.
Stocks to Consider
Some better-ranked stocks in the broader medical space include Thermo Fisher Scientific Inc. (TMO - Free Report) , McKesson Corporation (MCK - Free Report) and Cerner Corporation .
Thermo Fisher’s long-term earnings growth rate is estimated at 14%. The company’s earnings yield of 3.7% compares favorably with the industry’s (3.6%).
McKesson beat earnings estimates in each of the trailing four quarters, the average surprise being 19.9%. The company currently carries a Zacks Rank #2.
McKesson’s long-term earnings growth rate is estimated at 8.9%. The company’s earnings yield of 9.9% compares favorably with the industry’s 3.2%.
Cerner surpassed earnings estimates in each of the trailing four quarters, the average surprise being 3.2%. The company currently carries a Zacks Rank of 2.
Cerner’s long-term earnings growth rate is estimated at 13.3%. The company’s earnings yield of 4.6% compares favorably with the industry’s (5.4%).
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Shutterstock
Avanos Medical's (AVNS) App to Support Pain Management Process
Avanos Medical, Inc. (AVNS - Free Report) recently introduced its PainBlock Pro data collection and patient engagement app that enables healthcare providers to track patients’ recovery in real time for up to 10 days after surgery. The app/text message-based platform is easy to use and helps in tracking patient progress by collecting patient reported outcomes (PROs) through quick daily surveys, pre and post surgery, via the completion of the pain management therapy.
The launch of this app is another addition to Avanos Medical’s robust product portfolio, which is a significant contributor to the company’s top line.
Benefits of the New Technology
Per management, gathering real-time patient feedback forms a crucial step in getting patients back to the important things. The app helps healthcare providers to communicate with their patients with user-friendly technology, which gives key insight into the recovery process.
Data collected from the aforementioned surveys can allow providers to develop customized pain management plans on the basis of critical factors that include patients’ level of pain, opioid consumption and overall satisfaction.
Market Prospects
Per a report by Grand View Research, the global patient engagement solutions market was worth $15.1 billion in 2020 and is projected to witness a CAGR of 21.4% from 2021 to 2028. Growing utilization of electronic health records for patient-centric care and the adoption of mobile health devices are the primary factors driving this market’s growth. Hence, this launch is well-timed for Avanos Medical.
Recent Development
Per the third-quarter 2021 earnings call, Avanos Medical continues to improve its product offerings entering the fourth quarter of the year to boost the efficacy and ease of use for its care partners.
Price Performance
Shares of this Zacks Rank #3 (Hold) company have lost 35.2% on a year-to-date basis against the industry’s growth of 3%.
Stocks to Consider
Some better-ranked stocks in the broader medical space include Thermo Fisher Scientific Inc. (TMO - Free Report) , McKesson Corporation (MCK - Free Report) and Cerner Corporation .
Thermo Fisher surpassed earnings estimates in each of the trailing four quarters, the average surprise being 9.02%. The company currently carries a Zacks Rank of 2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Thermo Fisher’s long-term earnings growth rate is estimated at 14%. The company’s earnings yield of 3.7% compares favorably with the industry’s (3.6%).
McKesson beat earnings estimates in each of the trailing four quarters, the average surprise being 19.9%. The company currently carries a Zacks Rank #2.
McKesson’s long-term earnings growth rate is estimated at 8.9%. The company’s earnings yield of 9.9% compares favorably with the industry’s 3.2%.
Cerner surpassed earnings estimates in each of the trailing four quarters, the average surprise being 3.2%. The company currently carries a Zacks Rank of 2.
Cerner’s long-term earnings growth rate is estimated at 13.3%. The company’s earnings yield of 4.6% compares favorably with the industry’s (5.4%).